Department of Otolaryngology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
Endoscopic Nasal and Sinus Surgery Excellent Center, King Chulalongkorn Memorial Hospital, Bangkok, Thailand.
Curr Allergy Asthma Rep. 2021 Mar 25;21(4):25. doi: 10.1007/s11882-021-00999-9.
To assess the effects of herbal medicine (HM) therapy in various durations and analyze the effects of HM separately by mechanism of action in the treatment of allergic rhinitis (AR).
Thirty-two studies were included (2,697 patients, mean age 34.6 years). For the ≤ 4 weeks of treatment duration, HM brought greater benefits over placebo in reduction of total nasal symptoms score (standardized mean difference (SMD) -0.68; 95% confidence interval (CI) -0.98, -0.38; p <0.01) and improvement in Rhinoconjunctivitis Quality of Life Questionnaire score (SMD -0.53; 95% CI -0.81, -0.25; p <0.01). For the 4-12 weeks duration, total nasal symptoms score (SMD -0.22; 95%CI -0.4, -0.05; p =0.01) and Rhinoconjunctivitis Quality of Life Questionnaire score (SMD -0.48; 95% CI -0.89, -0.06; p =0.03) favored the HM. However, HM therapy for longer than 12 weeks was related to tachyphylaxis and showed no benefit over placebo in any outcomes. There was no difference between the HM and standard treatment on symptoms improvement. Anti-allergic effect, anti-inflammatory effect, anti-leukotriene effect, and anti-histaminic effect of HM were revealed. HM was safe and their adverse effects were comparable placebo. HM therapy is safe and provides better results than placebo in improving nasal symptoms and disease-specific quality of life in patients with AR. Its beneficial effects are demonstrated only in less than 12 weeks of treatment.
PROSPERO ID: CRD42020168367.
评估草药（HM）疗法在不同时间内的疗效，并按作用机制分别分析 HM 治疗变应性鼻炎（AR）的效果。
纳入 32 项研究（2697 例患者，平均年龄 34.6 岁）。治疗时间≤4 周时，HM 较安慰剂更能显著降低总鼻部症状评分（标准化均数差（SMD）-0.68；95%置信区间（CI）-0.98，-0.38；p<0.01）和改善鼻结膜炎生活质量问卷评分（SMD-0.53；95%CI-0.81，-0.25；p<0.01）。治疗时间为 4-12 周时，总鼻部症状评分（SMD-0.22；95%CI-0.4，-0.05；p=0.01）和鼻结膜炎生活质量问卷评分（SMD-0.48；95%CI-0.89，-0.06；p=0.03）也更倾向于 HM。然而，HM 治疗时间超过 12 周与快速耐受有关，在任何结局上均无优于安慰剂的效果。HM 与标准治疗在症状改善方面无差异。HM 具有抗过敏、抗炎、抗白三烯和抗组胺作用。HM 治疗安全，不良反应与安慰剂相当。HM 治疗可安全改善 AR 患者的鼻部症状和疾病特异性生活质量，疗效优于安慰剂，且仅在 12 周内治疗有效。
PROSPERO 注册号：CRD42020168367。
